Back to search results

MOHs Surgery and Short-Course Radiation Therapy for Head & Neck Skin Cancer

This study is looking at two ways to treat a type of skin cancer called cutaneous squamous cell carcinoma (cSCC) in the head and neck area after surgery. For patients with high-risk cSCC, researchers are testing if short-course radiation therapy (5 treatments over 2 weeks) can effectively prevent the cancer from coming back. For patients with moderate-risk cSCC, the study is investigating if active surveillance (close monitoring without immediate radiation) is a safe option. The main goal is to see how well short-course radiation prevents recurrence in high-risk patients and if active surveillance is safe for moderate-risk patients. The study plans to enroll 24 participants.

Study design
This interventional study plans to enroll 24 participants. It compares short-course radiation therapy for high-risk patients with active surveillance for moderate-risk patients.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will measure how often the cancer comes back in the treated area at 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06998342

MOHs Surgery and Short-Course Radiation Therapy With Structured Follow-Up for Head & Neck Squamous Cell Skin Cancer

Recruiting
PHASE2Ages 18+InterventionalTreatment
University of Vermont Medical Center
~24 participants
Updated 2026-05-26 on ClinicalTrials.gov
What's tested:Short course radiationActive Surveillance

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Exploring the Efficacy of Adjuvant Hypofractionated Radiation Therapy in High-Risk cSCC Head and Neck Patients: A Comparison of 2-Year Locoregional Recurrence Rates
Measured over 2 years

Conditions

Cutaneous Squamous Cell Carcinoma (CSCC)

Explore related trials

Skin Squamous Cell Carcinoma

NCT06998342

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Vermont Medical Center

    Burlington, Vermontstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Christopher Anker, MD
[email protected]
(802) 656-2021
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Pathologically confirmed cutaneous squamous cell carcinoma of the head \& neck region, defined as extending from vertex of head to supraclavicular region.
Mohs micrographic surgery with or without further surgery following Mohs to achieve negative margins (i.e. R0 margin status) within 70 days prior to registration
Appropriate stage for study entry (T1-T3 N0 M0; AJCC 8th ed.) based on the following diagnostic workup:
Clinical exam within 60 days prior to registration
CT head \& neck/soft tissue with IV contrast within 60 days prior to registration or MR face and neck with IV contrast. IV contrast may be held if medically contraindicated.
Bilateral neck ultrasound within 60 days prior to registration
Risk Factors fitting either the High-Risk or Moderate-Risk Categories:
Risk Factor Definitions

Exclusion

Patients receiving any other investigational agents.

What this trial measures

  • Exploring the Efficacy of Adjuvant Hypofractionated Radiation Therapy in High-Risk cSCC Head and Neck Patients: A Comparison of 2-Year Locoregional Recurrence Rates2 years

    To explore the potential efficacy of adjuvant hypofractionated radiation therapy (SCRT) in high-risk cutaneous squamous cell carcinoma (cSCC) head and neck patients by examining the 2-year locoregional recurrence rate (LRR) and comparing it to historical controls who received standard long-course radiation therapy (LCRT). Considering the variability in LRR among patients eligible for SCRT, the researchers aim to investigate whether a 2-year LRR \<25% could be achieved.